About Legend Biotech Corporation
https://www.legendbiotech.comLegend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally.
CEO
Ying Huang
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 161
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
UBS
Buy
HC Wainwright & Co.
Buy
Truist Securities
Buy
RBC Capital
Outperform
Cantor Fitzgerald
Overweight
Morgan Stanley
Overweight
Grade Summary
Showing Top 6 of 9
Price Target
Institutional Ownership
FMR LLC
Shares:27.7M
Value:$644.92M
WESTFIELD CAPITAL MANAGEMENT CO LP
Shares:6.09M
Value:$141.88M
HHLR ADVISORS, LTD.
Shares:5.98M
Value:$139.32M
Summary
Showing Top 3 of 220
About Legend Biotech Corporation
https://www.legendbiotech.comLegend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $272.33M ▲ | $200.48M ▲ | $-39.69M ▲ | -14.57% ▲ | $-0.42 ▲ | $-33.19M ▲ |
| Q2-2025 | $255.06M ▲ | $178.95M ▲ | $-125.38M ▼ | -49.16% ▲ | $-1.36 ▼ | $-113.72M ▼ |
| Q1-2025 | $195.05M ▲ | $174.36M ▼ | $-100.92M ▼ | -51.74% ▼ | $-1.1 ▼ | $-88.87M ▼ |
| Q4-2024 | $186.52M ▲ | $187M ▲ | $26.28M ▲ | 14.09% ▲ | $0.28 ▲ | $52.46M ▲ |
| Q3-2024 | $160.21M | $174.79M | $-125.32M | -78.23% | $-1.36 | $-109.91M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $992.59M ▲ | $1.71B ▲ | $701.69M ▲ | $1.01B ▼ |
| Q2-2025 | $967.55M ▼ | $1.69B ▲ | $654.38M ▲ | $1.04B ▲ |
| Q1-2025 | $1.01B ▼ | $1.62B ▼ | $597.9M ▼ | $1.02B ▼ |
| Q4-2024 | $1.12B ▼ | $1.67B ▼ | $629.61M ▲ | $1.04B ▼ |
| Q3-2024 | $1.21B | $1.74B | $619.72M | $1.12B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-39.07M ▲ | $28.8M ▲ | $-20M ▲ | $670K ▲ | $12.31M ▲ | $23.8M ▲ |
| Q2-2025 | $-124.8M ▼ | $-13.04M ▲ | $-165.53M ▼ | $-990K ▼ | $-175.12M ▼ | $-22.27M ▲ |
| Q1-2025 | $-99.13M ▼ | $-103.75M ▼ | $256.64M ▲ | $667K ▲ | $154.95M ▲ | $-105.76M ▼ |
| Q4-2024 | $40.51M ▲ | $-82.08M ▼ | $-87.84M ▼ | $-333K ▼ | $-172.53M ▼ | $-84.46M ▼ |
| Q3-2024 | $-120.89M | $-75.82M | $329.08M | $4.25M | $258.02M | $-77.89M |
CEO
Ying Huang
Compensation Summary
(Year )
ETFs Holding This Stock
Summary
Showing Top 3 of 161
Ratings Snapshot
Rating : C-
Most Recent Analyst Grades
UBS
Buy
HC Wainwright & Co.
Buy
Truist Securities
Buy
RBC Capital
Outperform
Cantor Fitzgerald
Overweight
Morgan Stanley
Overweight
Grade Summary
Showing Top 6 of 9
Price Target
Institutional Ownership
FMR LLC
Shares:27.7M
Value:$644.92M
WESTFIELD CAPITAL MANAGEMENT CO LP
Shares:6.09M
Value:$141.88M
HHLR ADVISORS, LTD.
Shares:5.98M
Value:$139.32M
Summary
Showing Top 3 of 220